Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Quantum Biopharma Ltd. on October 28, 2025. The filing covers the month of October 2025 and serves to incorporate by reference a series of Material Change Reports (Exhibits 99.1 through 99.11) into the company's Registration Statement on Form F-3 (File No. 333-276264). The company is headquartered in Toronto, Ontario.
Key Financial Metrics
The provided filing text does not contain specific financial data. There are no disclosed values for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing functions solely as a mechanism to update the registration statement with referenced material change reports.
Material Changes
The filing incorporates eleven Material Change Reports spanning from February 2024 to September 2025. While the specific content of these changes is not detailed in the text provided, the dates of the reports are as follows:
- February 6, 2024
- February 26, 2024
- July 3, 2024
- August 23, 2024
- August 29, 2024
- September 13, 2024
- September 19, 2024
- October 3, 2024
- March 17, 2025
- June 27, 2025
- September 30, 2025
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. It does not disclose any unusual items or contingencies beyond the existence of the referenced material changes.
Investor Verification Checklist
- Review the full text of Exhibits 99.1 through 99.11 to understand the specific nature of the material changes reported between February 2024 and September 2025.
- Verify the status of the Registration Statement on Form F-3 (File No. 333-276264) to determine if the incorporated changes affect the company's capital raising capabilities.
- Confirm the company's current financial position through separate filings (e.g., Form 20-F or quarterly reports) as this document contains no financial metrics.